Literature DB >> 17334512

Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication.

Paolo Gresele1, Rino Migliacci, Alessandra Procacci, Paola De Monte, Erminio Bonizzoni.   

Abstract

Ischemia/reperfusion damage evokes systemic inflammation and endothelial dysfunction in patients with intermittent claudication. We compared the effects of aspirin with those of a nitric oxide-donating aspirin in preventing the acute, systemic endothelial dysfunction provoked by exercise-induced ischemia of the lower limbs in patients with intermittent claudication. In a prospective, randomized, single-blind, parallel-groups trial among 44 patients with intermittent claudication we compared four weeks of aspirin (100 mg o.d.) with NCX 4016 (800 mg b.i.d.). Primary end point was the exercise-induced changes in brachial flow-mediated vasodilation (FMD) at day 28; secondary end points were effort-induced changes of markers of neutrophil (plasma elastase) and endothelial (soluble VCAM-1) activation. Baseline FMD was comparable in the two groups, both on day 1 (pre-treatment: aspirin = 3.1 +/- 0.5%, nitroaspirin = 3.9 +/- 0.7%, p = NS), and on day 28 (aspirin = 3.4 +/- 0.7%, NCX 4016 = 3.2 +/- 0.6%, p = NS). Maximal treadmill exercise induced an acute worsening of FMD in both groups at baseline (aspirin = -1.15%, nitroaspirin = -1.76%); after four weeks treatment, the impairment of FMD induced by exercise was still present in the aspirintreated group (-1.46%) while it was abolished in the NCX 4016-treated group (+0.79%, p = 0.038 vs. aspirin). Similarly, exercise induced an increase of plasma elastase and of sVCAM-1 which were not affected by aspirin while they were suppressed by NCX 4016. Maximal treadmill exercise induces a systemic arterial endothelial dysfunction in patients with intermittent claudication. A nitric oxide-donating aspirin, but not aspirin, prevents effort-induced endothelial dysfunction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17334512

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  10 in total

1.  Critical limb ischemia.

Authors:  Paolo Gresele; Chiara Busti; Tiziana Fierro
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

Review 2.  Building a better aspirin: gaseous solutions to a century-old problem.

Authors:  J L Wallace
Journal:  Br J Pharmacol       Date:  2007-07-16       Impact factor: 8.739

3.  Comparative effects of cilostazol and aspirin on the impairment of endothelium-dependent cerebral vasodilation caused by acute cigarette smoking in rats.

Authors:  Hiroki Iida; Mami Iida; Motoyasu Takenaka; Naokazu Fukuoka; Shuji Dohi
Journal:  J Thromb Thrombolysis       Date:  2010-05       Impact factor: 2.300

4.  Hyperglycemia-induced platelet activation in type 2 diabetes is resistant to aspirin but not to a nitric oxide-donating agent.

Authors:  Paolo Gresele; Stefania Marzotti; Giuseppe Guglielmini; Stefania Momi; Silvia Giannini; Pietro Minuz; Paola Lucidi; Geremia B Bolli
Journal:  Diabetes Care       Date:  2010-03-18       Impact factor: 19.112

Review 5.  Platelet function profiles in patients with diabetes mellitus.

Authors:  Fabiana Rollini; Francesco Franchi; Ana Muñiz-Lozano; Dominick J Angiolillo
Journal:  J Cardiovasc Transl Res       Date:  2013-02-13       Impact factor: 4.132

Review 6.  Carbon Monoxide and Nitric Oxide as Examples of the Youngest Class of Transmitters.

Authors:  Alicja Nowaczyk; Magdalena Kowalska; Jacek Nowaczyk; Grzegorz Grześk
Journal:  Int J Mol Sci       Date:  2021-06-02       Impact factor: 5.923

7.  Emerging antiplatelet agents, differential pharmacology, and clinical utility.

Authors:  Pranab Das; Carrie S Oliphant; Elizabeth Beach; Rashmi Thapa
Journal:  J Blood Med       Date:  2010-05-31

8.  Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy.

Authors:  Karthik Balasubramaniam; Girish N Viswanathan; Sally M Marshall; Azfar G Zaman
Journal:  Cardiol Res Pract       Date:  2012-01-05       Impact factor: 1.866

9.  Role of endothelial dysfunction in the thrombotic complications of COVID-19 patients.

Authors:  Emanuela Falcinelli; Eleonora Petito; Cecilia Becattini; Edoardo De Robertis; Ugo Paliani; Manuela Sebastiano; Gaetano Vaudo; Giuseppe Guglielmini; Francesco Paciullo; Vittorio Cerotto; Marco Malvestiti; Fabio Gori; Loredana Bury; Teseo Lazzarini; Paolo Gresele
Journal:  J Infect       Date:  2020-12-02       Impact factor: 6.072

Review 10.  Can the measurement of brachial artery flow-mediated dilation be applied to the acute exercise model?

Authors:  Jaume Padilla; Ryan A Harris; Janet P Wallace
Journal:  Cardiovasc Ultrasound       Date:  2007-11-26       Impact factor: 2.062

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.